Erasca, Inc. financial data

Symbol
ERAS on Nasdaq
Industry
Pharmaceutical Preparations
Location
10835 Road To The Cure, Suite 140, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.25K % +2.22%
Debt-to-equity 22.6 % +0.49%
Return On Equity -45.4 % +26.5%
Return On Assets -37 % +26.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 283M shares +87%
Common Stock, Shares, Outstanding 273M shares +81.6%
Entity Public Float 297M USD -31.2%
Common Stock, Value, Issued 27K USD +80%
Weighted Average Number of Shares Outstanding, Basic 218M shares +45.2%
Weighted Average Number of Shares Outstanding, Diluted 218M shares +45.2%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 41M USD +11.8%
Operating Income (Loss) -175M USD +29.4%
Nonoperating Income (Expense) 16.9M USD +37.1%
Net Income (Loss) Attributable to Parent -158M USD +32.9%
Earnings Per Share, Basic -0.92 USD/shares +49.2%
Earnings Per Share, Diluted -0.92 USD/shares +49.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 173M USD +24.5%
Marketable Securities, Current 236M USD +32%
Cash, Cash Equivalents, and Short-term Investments 408M USD +28.8%
Assets, Current 418M USD +29.1%
Property, Plant and Equipment, Net 18M USD -24.8%
Operating Lease, Right-of-Use Asset 33.5M USD -14.4%
Other Assets, Noncurrent 3.96M USD -24.6%
Assets 526M USD +19.3%
Accounts Payable, Current 2.14M USD -18.6%
Liabilities, Current 24.9M USD +6.87%
Operating Lease, Liability, Noncurrent 49.7M USD -7.94%
Other Liabilities, Noncurrent 82K USD -88.2%
Liabilities 74.7M USD -4.23%
Accumulated Other Comprehensive Income (Loss), Net of Tax -196K USD +75.3%
Retained Earnings (Accumulated Deficit) -704M USD -29%
Stockholders' Equity Attributable to Parent 451M USD +24.4%
Liabilities and Equity 526M USD +19.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.3M USD -26.2%
Net Cash Provided by (Used in) Financing Activities 6.93M USD +3687%
Net Cash Provided by (Used in) Investing Activities 9.97M USD -32.2%
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 273M shares +80.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.3M USD -42.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 173M USD +24.4%
Deferred Tax Assets, Valuation Allowance 144M USD +10.5%
Deferred Tax Assets, Gross 156M USD +6.13%
Operating Lease, Liability 54M USD -6.37%
Payments to Acquire Property, Plant, and Equipment 42K USD -96.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -158M USD +33%
Lessee, Operating Lease, Liability, to be Paid 76.2M USD -10.2%
Property, Plant and Equipment, Gross 26.3M USD -9.98%
Operating Lease, Liability, Current 4.29M USD +16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.17M USD +1.62%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.02M USD +3.11%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22.2M USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.2M USD +0.32%
Deferred Tax Assets, Operating Loss Carryforwards 59.3M USD +13.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 80M shares 0%
Unrecognized Tax Benefits 4.1M USD +50.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.28M USD +0.85%
Operating Lease, Payments 2.1M USD +143%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.98M USD +12%
Share-based Payment Arrangement, Expense 26.4M USD +7.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%